Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)
June 17 2022 - 5:29PM
Edgar (US Regulatory)
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
For the month of June 2022
Commission File Number 001-38512
Oncolytics Biotech Inc.
(Translation of registrant’s name into
English)
Suite 804, 322 11th Avenue SW
Calgary, Alberta, Canada T2R 0C5
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual
reports under cover Form 20-F or Form 40-F.
Indicate by check mark if the registrant is submitting
the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): o
Note: Regulation S-T Rule 101(b)(1)
only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.
Indicate by check mark if the registrant is submitting
the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): o
Note: Regulation S-T Rule 101(b)(7)
only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign
private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally
organized (the registrant’s “home country”), or under the rules of the home country exchange on which the registrant’s
securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed
to the registrant’s security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission
or other Commission filing on EDGAR.
INCORPORATION BY REFERENCE
Exhibit 99.1 included with this report on Form 6-K are expressly incorporated
by reference into this report and are hereby incorporated by reference as exhibits to the Registration Statement on Form F-10 of Oncolytics
Biotech Inc. (File No. 333-265510), as amended or supplemented.
DOCUMENTS FILED
See the Exhibit Index hereto.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
|
Oncolytics Biotech Inc.
(Registrant) |
|
|
|
|
|
Date: June 17, 2022 |
|
By: |
|
/s/ Kirk Look
|
|
|
|
|
|
|
|
|
|
Kirk Look |
|
|
|
|
Chief Financial Officer |
EXHIBIT INDEX
Oncolytics Biotech (NASDAQ:ONCY)
Historical Stock Chart
From Mar 2024 to Apr 2024
Oncolytics Biotech (NASDAQ:ONCY)
Historical Stock Chart
From Apr 2023 to Apr 2024